middle.news
Recce finds regional partner for RECCE 327 ahead of key Phase 3 review
9:45am on Thursday 22nd of October, 2026 AEDT
•
Biotechnology
Read Story
Recce finds regional partner for RECCE 327 ahead of key Phase 3 review
9:45am on Thursday 22nd of October, 2026 AEDT
Key Points
Exclusive Australia and New Zealand commercialisation rights for Arrotex
Recce retains manufacturing, supply and intellectual property ownership
Significant gross-margin profit share with no upfront or milestone payments
R327G remains in registrational Phase 3 development and is not approved
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE